Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingzhen Zhou

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Frontiers in Pharmacology|June 3, 2022
Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant <i>Staphylococcus aureus</i>: A Network Meta-AnalysisXiaonan Xu, Ni Lu, Pan Song, et al.
Clinical & Translational Immunology|January 15, 2024
A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancerMingzhen Zhou, Yuncheng Jin, Sihui Zhu, et al.
Cancer Biology & Medicine|August 9, 2023
Regulatory role of exosomes in colorectal cancer progression and potential as biomarkersJuan Hui, Mingzhen Zhou, Guangzhou An, et al.
Frontiers in Oncology|July 16, 2026
LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapyJuan Zhang, Mingzhen Zhou, Ziyue Jin, et al.
BMC Cancer|July 7, 2024
KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancerSihui Zhu, Yuncheng Jin, Mingzhen Zhou, et al.
Head & Neck|December 31, 2013
Prognostic model for distant metastasis in locally advanced nasopharyngeal carcinoma after concurrent chemoradiotherapyChuangzhen Chen, Siqia Chen, Quynh-Thu Le, et al.
Cancer Medicine|November 6, 2023
Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective studyJingyi Guo, Qun Zhou, Mingzhen Zhou, et al.
Asian Journal of Surgery|April 19, 2021
Transperitoneal versus retroperitoneal approaches of pyeloplasty in management of ureteropelvic junction obstruction: A meta-analysisPan Song, Mengxuan Shu, Zhufeng Peng, et al.
Journal of Hepatocellular Carcinoma|February 13, 2024
Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving RadiotherapyZhan Shi, Sihui Zhu, Yuncheng Jin, et al.
Hepatobiliary Surgery and Nutrition|November 7, 2024
A novel nomogram for predicting the prognosis of hepatocellular carcinoma patients following immune checkpoint inhibitors treatment beyond progression: a single center study based on Chinese populationChao Chen, Xiaoyuan Chu, Hong Liu, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Frontiers in Pharmacology|June 3, 2022
Vancomycin, Daptomycin, Antistaphylococcal β-Lactam, and Trimethoprim-Sulfamethoxazole Monotherapy and Combination Therapy in the Management of Methicillin-Resistant <i>Staphylococcus aureus</i>: A Network Meta-AnalysisXiaonan Xu, Ni Lu, Pan Song, et al.
Clinical & Translational Immunology|January 15, 2024
A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancerMingzhen Zhou, Yuncheng Jin, Sihui Zhu, et al.
Cancer Biology & Medicine|August 9, 2023
Regulatory role of exosomes in colorectal cancer progression and potential as biomarkersJuan Hui, Mingzhen Zhou, Guangzhou An, et al.
Frontiers in Oncology|July 16, 2026
LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapyJuan Zhang, Mingzhen Zhou, Ziyue Jin, et al.
BMC Cancer|July 7, 2024
KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancerSihui Zhu, Yuncheng Jin, Mingzhen Zhou, et al.
Head & Neck|December 31, 2013
Prognostic model for distant metastasis in locally advanced nasopharyngeal carcinoma after concurrent chemoradiotherapyChuangzhen Chen, Siqia Chen, Quynh-Thu Le, et al.
Cancer Medicine|November 6, 2023
Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective studyJingyi Guo, Qun Zhou, Mingzhen Zhou, et al.
Asian Journal of Surgery|April 19, 2021
Transperitoneal versus retroperitoneal approaches of pyeloplasty in management of ureteropelvic junction obstruction: A meta-analysisPan Song, Mengxuan Shu, Zhufeng Peng, et al.
Journal of Hepatocellular Carcinoma|February 13, 2024
Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving RadiotherapyZhan Shi, Sihui Zhu, Yuncheng Jin, et al.
Hepatobiliary Surgery and Nutrition|November 7, 2024
A novel nomogram for predicting the prognosis of hepatocellular carcinoma patients following immune checkpoint inhibitors treatment beyond progression: a single center study based on Chinese populationChao Chen, Xiaoyuan Chu, Hong Liu, et al.
Pageof 3